Close Menu

People in the News

Apr 24, 2019

Andrew Last

Bio-Rad Laboratories has appointed Andrew Last as executive VP and chief operating officer, responsible for all operating functions of the company on a global basis. Last was most recently CCO at Berkeley Lights and prior to that he served as COO at Intrexon. He was executive VP and COO at Affymetrix between 2010 and 2016, and has also previously held senior positions at Becton Dickinson, Applied Biosystems, Incyte Genomics, and Monsanto.

Apr 23, 2019

Bahija Jallal

Guardant Health has appointed Bahija Jallal to its board of directors, effective April 17. Jallal has served as the CEO of Immunocore Limited, a T cell receptor biotechnology company, since January 2019. Prior to that she served as executive VP of AstraZeneca and was president of MedImmune, a subsidiary of AstraZeneca, after holding various other research and development positions at the firm. Jallal is a member of the board of trustees at Johns Hopkins University and of UMB Health Sciences Research Park. She has also served as a past president of the Association for Women in Science.

Apr 23, 2019

Joseph Frendo

Caris Life Sciences announced Joseph Frendo has joined the company as chief operations officer. He was senior vice president of PBM Operations at CVS health. Prior to that, he held various management positions at Medco Health Solutions. In his role at Caris, Frendo will direct technical and clinical staff operations and guide strategies to advance quality and optimize efficiences across the firm, Caris said. 

Apr 23, 2019

Melody Harris

SomaLogic has appointed Melody Harris as the firm's president. Harris joined the firm as its chief legal officer in 2018 from Qualcomm Life. Harris previously served as general counsel at HealthyCircles before it was acquired by Qualcomm. Prior to HealthyCircles, Harris held a variety of executive leadership roles at a consulting firm in the broadcasting space. 

Apr 22, 2019

Richard Wenstrup

Epic Sciences has appointed Richard Wenstrup as its chief medical officer. Wenstrup has served in several clinical leadership roles managing life science companies in the past 25 years. Before Epic, he previously served as CMO for Oxford Immunotec, where he oversaw research and development, product development, regulatory, medical, and clinical affairs. From 2006 to 2017, Wenstrup served as CMO at Myriad Genetics. Prior to Myriad, Wenstrup was a pediatrics professor in human genetics at Cincinnati Children's Hospital Medical Center and professor of biomedical engineering at the University of Cincinnati. 

Apr 18, 2019

Ori Karev

Ori Karev has joined Precipio as chief strategy officer. Karev was formerly CEO of UnitedHealthcare Global, the international division of United Healthcare. He also previously worked for Ernst & Young. An attorney by training, Karev has more than 30 years of experience in the healthcare, insurance, and mobility industries, Precipio said.

Apr 17, 2019

Carsten Ullrich

Centogene has appointed Carsten Ullrich its director of artificial intelligence. He will direct the firm's use of AI to enhance diagnostic effectiveness and quality, and to discover new insights, accelerate biomarker development, and drive solutions for drug firms. Ullrich was most recently associate head of a research lab and senior researcher at the German Research Center for Artifidal Intelligence. 

Apr 16, 2019

Marijn Dekkers

Marijn Dekkers has been named chairman of the board of synthetic biology firm Ginkgo Bioworks. He also will serve as a strategic advisor of the Boston-based company. Dekkers most recently served as CEO of Bayer AG, and prior to that was CEO of Thermo Fisher Scientific. He also currently serves as chairman of Unilever and is founder and chairman of Novalis LifeSciences, a boutique investment and advisory firm.

Apr 15, 2019

James Corbett

PerkinElmer said recently that Executive Vice President and President of Discovery & Analytical Solution James Corbett is leaving the company on April 30. His departure follows a "conversation" between PerkinElmer and Corbett, the company said in a document filed with the US Securities and Exchange Commission. 

Apr 05, 2019

Andrew Brooks

Circuit Clinical, an integrated research organization that facilitates clinical trials and biospecimen collection, has added Andrew Brooks to its board of directors. Brooks is currently chief operating officer of RUCDR Infinite Biologics (RUCDR) at Rutgers University, the world's largest academic biorepository managing biological resources for clients such as the National Institutes of Health, as well as leading academic researchers and major pharmaceutical and biotechnology companies. He is a professor of genetics at Rutgers University and a member of the Human Genetics Institute of New Jersey.

Apr 05, 2019

Joseph Driscoll

Akoya Biosciences, which markets tools for high-parameter tissue analysis and biomarker discovery, has appointed Joseph Driscoll as CFO. Driscoll most recently served as CFO at Quanterix. He has also served as CFO at several other public and private companies, including Verscend, PC Connection, Summer Infant, ACT Electronics, and Safety 1[st].

Apr 03, 2019

Ilan Daskal

Bio-Rad Laboratories has appointed Ilan Daskal as executive vice president and CFO. Daskal previously served as CFO of Lumileds, a lighting manufacturer formed in 1999 as a joint venture between Philips Lighting and Agilent Technologies. He will replace Christine Tsingos, who is retiring.

Apr 03, 2019

James Marsden

LexaGene has appointed James Marsden to its scientific advisory board. Marsden previously served as the executive director of food safety at Chipotle from 2016 to 2019. According to LexaGene, Marsden has also worked for several food companies and techology providers. Prior to Chipotle, he acted as VP for scientific affairs and President at the American Meat Institute. In addition, Marsden also held the role of a professor at Kansas State University. 

Apr 02, 2019

Aaron Tachibana

Personalis has appointed Aaron Tachibana as CFO. Tachibana previously served as CFO of Lumentum Holdings. Prior to joining Lumentum, Tachibana was VP of finance at JDS Uniphase. He holds a BS in business administration and finance from San Jose State University. 

Apr 02, 2019

Flemming Ornskov

Flemming Ornskov was appointed to Centogene's supervisory board and elected its non-executive chairman, effective April 1. He most recently was CEO of Shire. Prior to that, he held senior positions at several pharmaceutical firms, such as Bayer, Novartis, and Merck & Co. As a non-executive chairman, Ornskov will oversee Centogene's strategy development, US expansion, and strategic M&A. 

Apr 01, 2019

Marc Williams, Karen Gripp, Dietrich Matern, Michael Murray, Cynthia Powell, Heidi Rehm

Marc Williams has been announced as president-elect of the American College of Medical Genetics and Genomics. He is the director of the Geisinger Genomic Medicine Institute. Prior to joining Geisinger in 2012, he was the director of Intermountain Healthcare's Clinical Genetics Institute. Williams is a board-certified pediatrician and holds an MD as well as an undergraduate degree in chemistry from the University of Wisconsin-Madison.

Williams and five others have also been elected to the ACMG's board of directors for a six-year term that starts this month. The other new directors are Karen Gripp, chief of the Division of Medical Genetics at the Nemours/Alfred I. duPont Hospital for Children and medical director of its molecular diagnostics laboratory; Dietrich Matern, chair of the Division of Laboratory Genetics and Genomics in the Department of Laboratory Medicine and Pathology at the Mayo Clinic; Michael Murray, director of clinical operations in the Center for Genomic Health at Yale University School of Medicine; Cynthia Powell, director of the medical residency program and medical director of the UNC Hospitals Cytogenetics Laboratory; and Heidi Rehm, chief genomics officer at Massachusetts General Hospital and medical director of the Broad Institute's clinical laboratory.

Mar 29, 2019

William Moss, Brandi Davis-Dusenbery

Seven Bridges has named promoted William Moss to CEO from his previous role as chief operations officer and president of commercial operations. He replaces Brandi Davis-Dusenbery, who has moved into the newly created position of chief scientific officer for the company. Davis-Dusenbery had been CEO since March 2017.

Mar 29, 2019

Amol Chaubal

Quanterix said this week that it has appointed Amol Chaubal as CFO, effective April 12, 2019. He replaces Joseph Driscoll, who is stepping down as CFO. Chaubal joins Quanterix from medical device firm Smith & Nephew, where he currently serves as CFO of global operations. Prior to Smith & Nephew, he served as corporate VP and head of finance for Parexel's CRS business, and has also held various roles at Novartis, including CFO North America – Vaccines & Diagnostics.

Mar 28, 2019

Bob Petrou

NantHealth has removed the "interim" tag from CFO Bob Petrou, company CEO Patrick Soon-Shiong disclosed today in a conference call with reporters and financial analysts. Petrou joined NantHealth in September following the resignation of former CFO Paul Holt.

Mar 27, 2019

Rob Treanor, Andrew Campbell

Sphere Fluidics has appointed Rob Treanor and Andrew Campbell as director of operations and director of finance, respectively. Treanor has previously held positions running large logistics and supply teams within the biotechnology sector. Campbell previously held senior positions at various global life sciences companies, including Charles Rivers and PerkinElmer Life Sciences.

Mar 27, 2019

Lloyd Sanders

Epic Sciences has appointed Lloyd Sanders as president and CEO. He will be replacing Murali Prahalad, who is stepping down and has been appointed to the board of directors. Sanders joins the firm with 20 years of diagnostic and pharmaceutical industry experience. He previously served as president of Myriad Genetics' oncology segment. Prior to Myriad, Sanders served as chief operating officer at Dey Pharma. Before Dey Pharma, Sanders worked at Genta, where he acted as VP of marketing and later COO.

Mar 22, 2019

John Niederhuber, Judy Garber, Geoffrey Ginsburg, Giovanni Parmigiani, David Rimm, Howard Scher

Konica Minolta Precision Medicine has announced the formation of its scientific advisory board, which include John Niederhuber, Judy Garber, Geoffrey Ginsburg, Giovanni Parmigiani, David Rimm, and Howard Scher. John Niederhuber has also been appointed as the board's chairman.

Niederhuber is currently CEO of the Genomics and Bioinformatics Research Institute, and formerly served as the director of the National Cancer Institute  and the National Institutes of Health.

Garber is currently chief of the division of cancer genetics and prevention at the Dana-Farber Cancer Institute, as well as a professor at Harvard Medical School.

Ginsburg currently serves as the founding director at the center for applied genomics & precision medicine at the Duke University Medical Center.

Parmigiani is currently associate director for population sciences of the multi-institutional Dana-Farber/Harvard Cancer Center, as well as director of the postdoctoral training grant in quantitative sciences for Cancer research at the Harvard T.H. Chan School of Public Health.

Rimm currently serves as professor of pathology and medicine at the Yale University School of Medicine, as well as the director of Yale Pathology Tissue Services.

Scher acts as the co-chair for mechanism based therapy and head of the biomarker development initiative at Memorial Sloan Kettering Cancer Center.

Mar 20, 2019

Ted Snelgrove

Liquid biopsy firm Lexent Bio has appointed Ted Snelgrove as its chief business officer. In the roll, Snelgrove will work closely with the CEO and  the company's board on test launch strategy, commercial team development, and corporate partnering.

Snelgrove's experience in molecular diagnostics includes building and leading the original commercial team for Genomic Health's Oncotype DX product line. He also built the commercial team at Crescendo Bioscience, now part of Myriad Genetics, promoting the firm's Vectra DA for disease management in rheumatology. He was CEO at CellScape, an early player in the NIPT market, served as the oncology/hematology business unit head at Jazz Pharmaceuticals, and held C-Level roles at Counsyl and more recently at Guardant Health.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.